Thompson Siegel & Walmsley LLC Has $33.51 Million Stock Holdings in Koninklijke Philips (NYSE:PHG)

Thompson Siegel & Walmsley LLC trimmed its holdings in shares of Koninklijke Philips (NYSE:PHG) by 21.2% during the 4th quarter, Holdings Channel reports. The institutional investor owned 1,323,362 shares of the technology company’s stock after selling 355,671 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in Koninklijke Philips were worth $33,508,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of PHG. Cable Hill Partners LLC acquired a new position in Koninklijke Philips during the third quarter valued at $203,000. Endowment Wealth Management Inc. acquired a new position in Koninklijke Philips during the third quarter valued at $205,000. PNC Financial Services Group Inc. raised its position in Koninklijke Philips by 4.8% during the third quarter. PNC Financial Services Group Inc. now owns 36,291 shares of the technology company’s stock valued at $1,187,000 after buying an additional 1,676 shares during the period. West Family Investments Inc. acquired a new position in Koninklijke Philips during the third quarter valued at $252,000. Finally, Charles Schwab Investment Management Inc. raised its position in Koninklijke Philips by 26.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 55,290 shares of the technology company’s stock valued at $1,809,000 after buying an additional 11,538 shares during the period. 13.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PHG has been the topic of a number of recent research reports. UBS Group upgraded Koninklijke Philips from a “neutral” rating to a “buy” rating in a research note on Thursday, February 20th. BNP Paribas upgraded Koninklijke Philips from a “neutral” rating to an “outperform” rating in a research note on Tuesday, February 25th. Finally, StockNews.com upgraded Koninklijke Philips from a “hold” rating to a “buy” rating in a research note on Saturday, March 8th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy”.

Koninklijke Philips Stock Performance

PHG opened at $26.66 on Thursday. The company has a market cap of $25.05 billion, a PE ratio of -31.73, a price-to-earnings-growth ratio of 0.82 and a beta of 0.78. The stock has a 50-day moving average of $26.59 and a 200-day moving average of $27.91. Koninklijke Philips has a 52-week low of $19.10 and a 52-week high of $32.91. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.74 and a current ratio of 1.23.

Koninklijke Philips (NYSE:PHG) last released its quarterly earnings results on Wednesday, February 19th. The technology company reported $0.54 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.55 by ($0.01). The company had revenue of $5.38 billion for the quarter, compared to the consensus estimate of $5.10 billion. Koninklijke Philips had a positive return on equity of 10.85% and a negative net margin of 3.88%. As a group, equities research analysts forecast that Koninklijke Philips will post 1.63 earnings per share for the current fiscal year.

Koninklijke Philips Cuts Dividend

The firm also recently announced an annual dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 13th will be paid a dividend of $0.886 per share. The ex-dividend date of this dividend is Tuesday, May 13th. This represents a yield of 2.9%. Koninklijke Philips’s payout ratio is -89.29%.

Koninklijke Philips Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.